Scientia Vascular has announced the US Food and Drug Administration (FDA) clearance of two uniquely engineered catheters: the Plato 17, a dimethyl sulfoxide (DMSO)-compatible microcatheter, and the Socrates 38, an aspiration catheter engineered for ischaemic stroke.
The introduction of the Plato 17 microcatheter and Socrates 38 aspiration catheter epitomises Scientia’s ethos of continuous innovation, according to a company press release.
Renowned for disrupting the industry with microfabricated guidewires, Scientia has applied the same groundbreaking technologies, design principles and precision machinery to “revolutionise” catheter manufacturing, the release adds, also noting that this distinct approach “exemplifies the company’s dedication to pushing the boundaries of medical technology”.
Currently in the midst of a limited market release, the Socrates 38 aspiration catheter is gathering valuable feedback and clinical insights. Scientia claims that this phase is “crucial” for executing the final stages of the strategic launch and bringing better, more advanced options to physicians treating stroke.
In addition, the Plato 17 microcatheter—compatible with DMSO—represents a “leap forward” in catheter design, offering physicians control and stability for a multitude of neurovascular applications. This innovation is a testament to Scientia’s ability to transfer groundbreaking technology from one product line to another, enhancing clinical value in patient treatment, the company further states.
“Our FDA clearance is a significant milestone for Scientia Vascular,” said John Lippert, chief executive officer of Scientia. “By applying proven microfabrication technology to catheters, and designing our access and treatment devices for efficiency when used together, we’re providing physicians the next generation of neurovascular access tools. I am immensely grateful to our dedicated teams whose tireless efforts have made this FDA clearance milestone possible. Their commitment to excellence and innovation continues to drive our patient mission forward.”
“We’ve seen what microfabrication can do—in products like our Aristotle 24 and Colossus wires—in changing the standard of care for patient treatment in stroke, so it’s rewarding to see the excitement and buzz surrounding microfabricated technology in catheters with our physician community,” added Paul Fischer, chief commercial officer for Scientia. “We are eager to see how these advanced technologies will enhance patient care and offer new possibilities for physicians treating a variety of neurovascular disease states.”
